Therapeutic Efficacy of CD34-Derived Allogeneic Dendritic Cells Engineered to Express CD93, CD40L, and CXCL13 in Humanized Mouse Models of Pancreatic Cancer

Therapeutic Efficacy of CD34-Derived Allogeneic Dendritic Cells Engineered to Express CD93, CD40L, and CXCL13 in Humanized Mouse Models of Pancreatic Cancer

<b>Background/Objectives</b>: Pancreatic cancer remains the fourth leading cause of cancer-related deaths. While peripheral blood-derived mature dendritic cell (mDC) vaccines have shown potential in eliciting anti-tumor immune responses, clinical efficacy has been limited. This study aim...

Full description

Saved in:
Bibliographic Details
Main Authors: Sara Huerta-Yepez, Jose D. Gonzalez, Neha Sheik, Senay Beraki, Elango Kathirvel, Ariel Rodriguez-Frandsen, Po-Chun Chen, Tiran Sargsyan, Saleemulla Mahammad, Mark R. Dybul, Lu Chen, Francois Binette, Anahid Jewett
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Vaccines
Subjects:
CD34 hematopoietic stem cells
dendritic cell therapy
CD40L
CD93
CXCL13
pancreatic cancer
Online Access:https://www.mdpi.com/2076-393X/13/7/749
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.mdpi.com/2076-393X/13/7/749

Similar Items